

Agency to Charge Drugmakers \$87M More in Fees

BY ALICIA AULT

Associate Editor, Practice Trends

The Food and Drug Administration on January 11 proposed greatly increasing the fees its drug division collects from pharmaceutical manufacturers, saying that current fees collected under the Prescription Drug User Fee Act have not kept pace with inflation or the agency's growing workload.

Most of the additional money would be

used to upgrade the agency's postmarketing drug safety monitoring. The FDA also is proposing to create a separate program to collect fees from companies that want their direct-to-consumer television ads reviewed by the agency.

The FDA published its proposals in the Jan. 11 Federal Register and will collect comments on them at a public meeting on Feb. 16. The final proposal will be sent to Congress later this year, said Jane Axelrad, associate director for policy at the Center

for Drug Evaluation and Research (CDER), in a teleconference sponsored by the FDA.

Time is of the essence, as PDUFA—first established in 1992 and reauthorized in 5-year increments—is due to expire Sept. 30.

Under PDUFA, the FDA charges prescription drugmakers a set fee to review the safety and efficacy of products submitted under a new drug application. In return, the agency has to meet deadlines for review and approval.

The law has helped FDA to reduce re-

view times and increase its postmarketing oversight, said Dr. Steven K. Galson, CDER director, during the teleconference.

Under the new proposal, FDA seeks to collect \$393 million annually, \$87 million more than it currently takes in each year. Drug user fees account for about half of CDER's budget, said Dr. Galson, adding that he could not say whether that would hold true going forward, since the agency has not yet received its appropriation for fiscal 2007 or a budget for fiscal 2008.

However, Ms. Axelrad said that drug user fees represent an increasing proportion of CDER's budget.

Public Citizen's Health Research Group criticized that trend, saying that the agency should not receive so much of its funding from the industry it regulates. "The FDA's crucial drug regulatory functions are too important to be tainted and compromised by direct funding from the very companies whose drugs the agency reviews for safety," said Dr. Sidney Wolfe, director of the advocacy group, in a statement.

The biotechnology and pharmaceutical industries praised the FDA proposal.

"The PDUFA recommendations announced today are a win-win," said Jim Greenwood, president and CEO of the Biotechnology Industry Organization, in a statement. "If enacted, they will help enhance and improve drug safety while providing resources to continue to enable efficient and comprehensive review of new drugs."

The largest portion of the increase, \$29 million, would be devoted to postmarketing safety. Some \$20 million would go to cover expenses incurred in the last few years to facilitate drugmakers' requests for formal meetings about their products. About \$4 million would be devoted to improving information technology for drug reviews, according to the FDA proposal.

FDA is proposing to create a new user fee program solely to fund the review of direct-to-consumer television ads. Companies can now voluntarily submit their ads for review, but the FDA has not been able to keep up with the growing workload, said Dr. Galson. ■

plateletNEWS.org

Breakthrough platelet information and education

FACULTY LIST

Dean J. Kereiakes, MD

The Heart Center of Greater Cincinnati and The Lindner Research Center at The Christ Hospital Cincinnati, Ohio

Norman E. Lepor, MD

Cedars-Sinai Medical Center Los Angeles, California

Peter B. Berger, MD

Geisinger Health System Danville, Pennsylvania

Marc Cohen, MD

Newark Beth Israel Hospital Newark, New Jersey

James J. Ferguson, MD

Texas Heart Institute at St. Luke's Episcopal Hospital Houston, Texas

Christopher B. Granger, MD

Duke University Medical Center Duke Clinical Research Institute Durham, North Carolina

Paul A. Gurbel, MD

Johns Hopkins University School of Medicine Sinai Hospital Baltimore, Maryland

Alan D. Michelson, MD

University of Massachusetts Medical School Worcester, Massachusetts

Gilles Montalescot, MD

Institut de Cardiologie Pitié-Salpêtrière Paris, France

Gregg W. Stone, MD

Columbia University Medical Center New York, New York

Stephen D. Wiviott, MD

Brigham and Women's Hospital Boston, Massachusetts

Introducing:

plateletNEWS.org/CN0207—dedicated to advancing knowledge in the diagnosis, prevention, and treatment of platelet-related thrombotic complications of cardiovascular disease.

plateletNEWS.org/CN0207 offers timely and comprehensive information through direct access to experts, CME and non-CME activities, literature reviews, late-breaking trial updates, clinical case scenarios, and more.

CME Center

- Video Webcasts on Relevant Issues
- Interactive Patient Case Scenarios
- Downloadable Slide Presentations
- Journal Clubs
- Textbook Chapters
- Review Articles

Expert Zone

- *Ask the Expert* section—pose questions to the expert of your choice on our committee
- *Welcome to My Practice*—showcase of prominent national cardiology institutions

Additional Resources

- Literature Reviews
- Article Reprints
- E-Newsletter

Visit
Elsevier's
ACC booth
#3947!

Visit plateletNEWS.org/CN0207 to enhance your understanding of platelet inhibition and thrombotic complications. Register today to receive timely educational materials.



CME
CONTINUING MEDICAL EDUCATION

This program is supported by an educational grant by Daiichi Sankyo, Inc. and Eli Lilly and Company. Certified CME activities on plateletNEWS.org/CN0207 have been planned and implemented in accordance with the Essential Areas and Policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint sponsorship of the Elsevier Office of Continuing Medical Education (EOCME) and Elsevier. The EOCME is accredited by the ACCME to provide continuing medical education for physicians.



INDEX OF ADVERTISERS

AstraZeneca LP.	
Crestor	31-32
Astellas Pharma US, Inc.	
Corporate	14-15
Biosite Incorporated	
Triage BNP Test	24
Daiichi Sankyo, Inc.	
Benicar	12a-12d
Medtronic, Inc.	
Pacemaker	26-28
Novartis Pharmaceuticals Corporation	
Lotrel	3-5
Pfizer Inc.	
Caduet	16-19
Scios Inc.	
Natreacor	8-11
Unetixs Vascular, Inc.	
Cruise Course	12
University of Pittsburgh Medical Center	
Corporate	23